A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Phase 1
75
about 2.6 years
18+
10 sites in CA, CT, FL +6
What this study is about
This trial is testing a new treatment called XB628 for people with advanced solid tumors. It's a phase 1 trial, meaning it's the first time this treatment is being tested in humans. The goal is to determine the best dose of XB628 and how well it works.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive XB628
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants with Dose Limiting Toxicities (DLTs), Number of Participants with Serious Adverse Events (SAEs), Treatment-emergent Adverse Events (TEAEs), and Adverse Events (AEs) Leading to Dose Withholding, Treatment Discontinuation, or Death
Secondary: Apparent Clearance (CL/F) of XB628, Area Under the Concentration-time Curve (AUC) of XB628, Duration of Response (DOR), Elimination Half-life (T1/2) of XB628, Maximum Plasma Concentration (Cmax) of XB628, Objective Response Rate (ORR), Time to Maximum Concentration (Tmax) of XB628
Oncology